# Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

> **NCT00967343** · PHASE2,PHASE3 · TERMINATED · sponsor: **Kiadis Pharma** · enrollment: 40 (actual)

## Conditions studied

- Myeloid Leukemia
- Lymphoblastic Leukemia
- Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Myeloproliferative Disorders

## Interventions

- **BIOLOGICAL:** Donor lymphocyte preparation depleted of host functional alloreactive T-cells

## Key facts

- **NCT ID:** NCT00967343
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967343, "Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00967343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*